CYP3A4-associated food drug interactions: The impact of combined intake of alprazolam with cranberry and pomegranate juice treating anxiety caused by kidney stones

Abstract

Nephrolithiasis is a common disease and incurs a significant burden on the health care system globally. Patients with kidney stones can be treated with natural remedy such as cranberry, pomegranate, and grape juice. Patients with kidney stone experience anxiety and insomnia as a result of the pain caused by the stones. As a result, physicians may prescribe anxiolytics to treat anxiety, among which alprazolam is a commonly prescribed medication. Meanwhile, cranberry and pomegranate juice are prescribed by many herbal specialists for the treatment of renal calculi. The enzyme CYP3A4 primarily metabolizes alprazolam, while fruit juices such as cranberry and pomegranate juices are potent inhibitors of CYP3A4. Therefore, there could be a drug-food interaction between alprazolam and cranberry and pomegranate juices when consumed concomitantly. A detailed pharmacodynamic and pharmacokinetic investigation is required to ascertain the food-drug interaction between alprazolam, cranberry, and pomegranate juice to avoid the possible toxicity of alprazolam. This review article provides insights about the possible CYP3A4-associated drug interactions between alprazolam and juices of cranberry and pomegranate, for the safe and effective usage of alprazolam in treating anxiety disorders caused by kidney stones.

Keywords

Alprazolam / Cranberry juice / Kidney stones / Anxiety / Pomegranate juice

Conflict of interest statement

The authors claim there is no conflict of interest.

Funding

This study receives no extramural funding.

Data availability statement

The data supporting the findings of this study are available from the corresponding author upon request.

Authors’ contributions

Narasappa KK involved in the design, data collection, analysis and interpretation, manuscript drafting, revision, and approval for publication. Kadiri SK carried out conception, design, data interpretation, manuscript drafting, revision and approval. Tiwari P and Bindigi R oversaw the data interpretation and revision. Kumar MV involved in manuscript drafting and revision.

References

[1] Ngo N, Yan Z, Graf TN, Carrizosa DR, Kashuba AD, Dees EC, et al. Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans. Drug Metab Dispos 2009; 37(3): 514-522.

[2] McHarg T, Rodgers A, Charlton K. Influence of cranberry juice on the urinary risk factors for calcium oxalate kidney stone formation. BJU Int 2013; 92(7): 765-768.

[3] Gillani HA, Khalid M, Said S, Khalid M, Umbreen S, Tariq S. Vitamin C and cranberry extract effervescent tablet formulation, characterization, and evaluation. Int J Pharm Integrat Health Sci 2023; 4(1): 3.

[4] Howell AB. Bioactive compounds in cranberries and their role in prevention of urinary tract infections. Mol Nutr Food Res 2007; 51(6): 732-737.

[5] Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: An update. Am Fam Physician 2011; 84(11): 1234-1242.

[6] Nemzer BV, Al-Taher F, Yashin A, Revelsky I, Yashin Y. Cranberry: Chemical composition, antioxidant activity and impact on human health: Overview. Molecules 2022; 27(5): 1503.

[7] Tracy CR, Henning JR, Newton MR, Aviram M, Zimmerman MB, et al. Oxidative stress and nephrolithiasis: A comparative pilot study evaluating the effect of pomegranate extract on stone risk factors and elevated oxidative stress levels of recurrent stone formers and controls. Urolithiasis 2014; 42(5): 401-408.

[8] Pappas E, Schaich KM. Phytochemicals of cranberries and cranberry products: characterization, potential health effects, and processing stability. Crit Rev Food Sci Nutr 2009; 49(9): 741-781.

[9] Gallo KP, Thompson-Hollands J, Pincus DB, Barlow DH. Anxiety disorders. In: Stricker G, Widiger TA, Weiner IB(Eds.). Handbook of psychology: Clinical psychology (2nd ed). Hoboken: John Wiley & Sons Inc; 2013, p. 147-170.

[10] Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Ame J Psychiatry 2005; 162(6): 1171-1178.

[11] Otani K. Cytochrome P450 3A4 and Benzodiazepines. Seishin Shinkeigaku Zasshi 2003; 105(5): 631-642.

[12] Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci 2015; 17(3): 327-335.

[13] Freeman D, Sheaves B, Waite F, Harvey AG, Harrison PJ. Sleep disturbance and psychiatric disorders. Lancet Psychiatry 2020; 7(7): 628-637.

[14] Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9(4): 310-322.

[15] Stein MB, Fuetsch M, Müller N, Höfler M, Lieb R, Wittchen HU. Social anxiety disorder and the risk of depression: A prospective community study of adolescents and young adults. Arch Gen Psychiatry 2001; 58(3): 251-256.

[16] Platt LM, Whitburn AI, Platt-Koch AG, Koch RL. Nonpharmacological alternatives to benzodiazepine drugs for the treatment of anxiety in outpatient populations: A literature review. J Psychosoc Nurs Ment Health Serv 2016; 54(8): 35-42.

[17] Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, et al. Drug metabolism in human brain: High levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 2008; 3(6): e2337.

[18] Ait-Daoud N, Hamby AS, Sharma S, Blevins D . A review of Alprazolam use, misuse, and withdrawal. J Addict Med 2018; 12(1): 4-10.

[19] Argyropoulos SV, Nutt DJ. The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol 1999; 9: S407-412.

[20] Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clinical pharmacokinetics 2000; 38: 41-57.

[21] Miyaoka R, Ortiz-Alvarado O, Kriedberg C, Alanee S, Chotikawanich E, Monga M. Correlation between stress and kidney stone disease. J Endourol 2012; 26(5): 551-555.

[22] Nuss P, Ferreri F, Bourin M. An update on the anxiolytic and neuroprotective properties of etifoxine: From brain GABA modulation to a whole-body mode of action. Neuropsychiatr Dis Treat 2019; 15: 1781-1795.

[23] VSO, Levi L . Long-term unemployment among women in Sweden. Soc Sci Med 1987; 25(2): 153-161.

[24] Goey AK, Mooiman KD, Beijnen JH, Schellens JH, Meijerman I. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients. Cancer Treat Rev 2013; 39(7): 773-783.

[25] Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clinical Pharmacokinet 1999; 36: 277-287.

[26] Starcevic V. Benzodiazepines for anxiety disorders: Maximising the benefits and minimising the risks. Adv Psychiatr Treat 2012; 18(4): 250-258.

[27] Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: Clinical relevance. Clin pharmacokinet 2003; 42: 819-850.

[28] Hohmann N, Haefeli WE, Mikus G. CYP3A activity: Towards dose adaptation to the individual. Expert Opin Drug Metab Toxicol 2016; 12(5): 479-497.

[29] Mansoor K, Bardees R, Alkhawaja B, Mallah E, AbuQatouseh L, Schmidt M, et al. Impact of pomegranate juice on the pharmacokinetics of CYP3A4-and CYP2C9-mediated drugs metabolism: A preclinical and clinical review. Molecules 2023; 28(5): 2117.